RxDoctor Payments Data

Christina Huynh, DO

Family Medicine · Portage, INNPI 1801180633

Payments from drug & device makers

$11,717in general payments, 2019–2025

Across 608 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$807
  • Pfizer$626
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$11,684100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,717 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$54,909
Medicare patients
146
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$98,735
JardianceEmpagliflozin63$56,418
TrulicityDulaglutide42$54,826
RybelsusSemaglutide39$52,778
FarxigaDapagliflozin Propanediol45$34,007
Soliqua 100-33Insulin Glargine/Lixisenatide24$25,588
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,135
EliquisApixaban29$18,301
XareltoRivaroxaban11$12,817
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$11,355
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,010
Repatha SureclickEvolocumab12$7,457
Xigduo XrDapaglifloz Propaned/Metformin11$6,303
Albuterol Sulfate HfaAlbuterol Sulfate71$1,844
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$1,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,146$151,513105 claims
Boehringer IngelheimJardiance$807$56,41863 claims
Lilly USA, LLCTrulicity$1,068$54,82642 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,130$45,36361 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$333$25,58824 claims
GSKTrelegy Ellipta$251$19,13529 claims
PfizerEliquis$626$18,30129 claims
Johnson & JohnsonXarelto$132$12,81711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Portage

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →